India, Aug. 10 -- Alpha Tau Medical Ltd. (DRTS), an Israeli oncology therapeutics company developing Alpha DaRT for solid tumors, on Monday announced plans to offer its ordinary shares on the Tel Aviv Stock Exchange or TASE and become dual-listed on Nasdaq and TASE.
The company has filed registration documents seeking to register its outstanding and potential future shares for dual listing on the TASE. The shares are expected to trade under the English symbol DRTS and the alternative Hebrew symbol.
The planned listing is intended to provide Israeli investors with access to Alpha Tau shares in local currency and during Israeli market hours, while expanding the company's presence in the local capital market.
googletag.cmd.push(function() {...